{
    "root": "3c8dca11-78ab-45c1-8bb2-89a41ea5dfa9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Gabapentin",
    "value": "20250501",
    "ingredients": [
        {
            "name": "GABAPENTIN",
            "code": "6CW7F3G59X"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "D&C RED NO. 33",
            "code": "9DBA0SBB0L"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        }
    ],
    "indications": "gabapentin indicated : • management postherpetic neuralgia adults •adjunctive therapy treatment partial onset seizures , without secondary generalization , adults pediatric patients 3 years older epilepsy",
    "contraindications": "• postherpetic neuralgia ( 2.1 ) dose titrated needed dose 1,800 mg/day day 1 : single 300 mg dose day 2 : 600 mg/day ( i.e . , 300 mg two times day ) day 3 : 900 mg/day ( i.e . , 300 mg three times day ) • epilepsy partial onset seizures ( 2.2 ) patients 12 years age older : starting dose 300 mg three times daily ; may titrated 600 mg three times daily patients 3 11 years age : starting dose range 10 15 mg/kg/day , given three divided doses ; recommended dose patients 3 4 years age 40 mg/kg/day , given three divided doses ; recommended dose patients 5 11 years age 25 35 mg/kg/day , given three divided doses . recommended dose reached upward titration period approximately 3 days • dose adjusted patients reduced renal function ( 2.3 , 2.4 )",
    "warningsAndPrecautions": "gabapentin capsules , usp supplied follows : 300 mg : capsules grey `` 300 mg `` imprinted white body grey `` oe b57 `` yellow cap . content white off-white powder . bottles 30 : ndc 82804-217-30 bottles 60 : ndc 82804-217-60 bottles 90 : ndc 82804-217-90",
    "adverseReactions": "gabapentin contraindicated patients demonstrated hypersensitivity ingredients .",
    "indications_original": "Gabapentin is indicated for:\n                  \n                     \n                        •\n                        Management of postherpetic neuralgia in adults\n                     \n                     \n                        •Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy",
    "contraindications_original": "• Postherpetic Neuralgia ( 2.1 ) o Dose can be titrated up as needed to a dose of 1,800 mg/day o Day 1: Single 300 mg dose o Day 2: 600 mg/day (i.e., 300 mg two times a day) o Day 3: 900 mg/day (i.e., 300 mg three times a day) • Epilepsy with Partial Onset Seizures ( 2.2 ) o Patients 12 years of age and older: starting dose is 300 mg three times daily; may be titrated up to 600 mg three times daily o Patients 3 to 11 years of age: starting dose range is 10 to 15 mg/kg/day, given in three divided doses; recommended dose in patients 3 to 4 years of age is 40 mg/kg/day, given in three divided doses; the recommended dose in patients 5 to 11 years of age is 25 to 35 mg/kg/day, given in three divided doses. The recommended dose is reached by upward titration over a period of approximately 3 days • Dose should be adjusted in patients with reduced renal function ( 2.3 , 2.4 )",
    "warningsAndPrecautions_original": "Gabapentin capsules, USP are supplied as follows:\n                  300 mg: Capsules with grey \"300 mg\" imprinted on the white body and grey \"OE B57\" on the yellow cap. The content is white or off-white powder.\n                  \n                     \n                         Bottles of 30: NDC 82804-217-30\n                     \n                         Bottles of 60: NDC 82804-217-60\n                     \n                         Bottles of 90: NDC 82804-217-90",
    "adverseReactions_original": "Gabapentin is contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients."
}